| Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2 … NL Busaidy, B Konda, L Wei, LJ Wirth, C Devine, GA Daniels, ... Thyroid 32 (10), 1184-1192, 2022 | 55 | 2022 |
| Developing drugs for tissue agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine ND Seligson, TC Knepper, S Ragg, CM Walko Clinical Pharmacology & Therapeutics, 2020 | 55 | 2020 |
| BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma ND Seligson, EA Kautto, EN Passen, C Stets, AE Toland, SZ Millis, ... The oncologist 24 (7), 973-979, 2019 | 55 | 2019 |
| Sacituzumab govitecan-hziy: an antibody-drug conjugate for the treatment of refractory, metastatic, triple-negative breast cancer JM Seligson, AM Patron, MJ Berger, RD Harvey, ND Seligson Annals of Pharmacotherapy 55 (7), 921-931, 2021 | 49 | 2021 |
| Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives MM Faheem, ND Seligson, SM Ahmad, RU Rasool, SG Gandhi, M Bhagat, ... Cell death discovery 6 (1), 51, 2020 | 42 | 2020 |
| Integration of EMT and cellular survival instincts in reprogramming of programmed cell death to anastasis S Chakraborty, KB Mir, ND Seligson, D Nayak, R Kumar, A Goswami Cancer and Metastasis Reviews 39, 553-566, 2020 | 37 | 2020 |
| Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma KLJ Bill, ND Seligson, JL Hays, A Awasthi, B Demoret, CW Stets, ... The oncologist 24 (7), 989-996, 2019 | 35 | 2019 |
| UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation RS Nelson, ND Seligson, S Bottiglieri, E Carballido, AD Cueto, I Imanirad, ... Cancers 13 (7), 1566, 2021 | 32 | 2021 |
| Clinical utility of CDK4/6 inhibitors in sarcoma: successes and future challenges JY Hsu, ND Seligson, JL Hays, WO Miles, JL Chen JCO Precision Oncology 6, e2100211, 2022 | 29 | 2022 |
| Common secondary genomic variants associated with advanced epithelioid hemangioendothelioma ND Seligson, A Awasthi, SZ Millis, BK Turpin, CF Meyer, A Grand'Maison, ... JAMA Network Open 2 (10), e1912416-e1912416, 2019 | 23 | 2019 |
| Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity ND Seligson, JL Warner, WS Dalton, D Martin, RS Miller, D Patt, KL Kehl, ... Journal of the American Medical Informatics Association 27 (11), 1808-1812, 2020 | 21 | 2020 |
| Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target ND Seligson, RD Maradiaga, CM Stets, HM Katzenstein, SZ Millis, ... NPJ Precision Oncology 5 (1), 43, 2021 | 14 | 2021 |
| Evaluation of the timing of MRSA PCR nasal screening: How long can a negative assay be used to rule out MRSA-positive respiratory cultures? SC Turner, ND Seligson, B Parag, KM Shea, ALV Hobbs American Journal of Health-System Pharmacy 78 (Supplement_2), S57-S61, 2021 | 13 | 2021 |
| Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma ND Seligson, CW Stets, BW Demoret, A Awasthi, N Grosenbacher, ... Oncotarget 10 (55), 5671, 2019 | 13 | 2019 |
| Evaluating the impact of the addition of cladribine to standard acute myeloid leukemia induction therapy ND Seligson, ALV Hobbs, JM Leonard, EL Mills, AG Evans, S Goorha Annals of Pharmacotherapy 52 (5), 439-445, 2018 | 13 | 2018 |
| XRCC1‐mediated DNA repair is associated with progression‐free survival of multiple myeloma patients after autologous stem cell transplant AK Persaud, J Li, JA Johnson, N Seligson, DW Sborov, E Duah, YK Cho, ... Molecular Carcinogenesis 58 (12), 2327-2339, 2019 | 11 | 2019 |
| Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML NHK Nguyen, R Rafiee, A Tagmount, A Sobh, A Loguinov, ... Blood Advances 7 (9), 1769-1783, 2023 | 8 | 2023 |
| Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas ND Seligson, J Tang, DX Jin, MP Bennett, JA Elvin, K Graim, JL Hays, ... NPJ Precision Oncology 6 (1), 29, 2022 | 7 | 2022 |
| Key considerations for selecting a genomic decision support platform for implementing pharmacogenomics. KJ Cook, BQ Duong, ND Seligson, P Arn, VL Funanage, KW Gripp, ... Clinical Pharmacology & Therapeutics 110 (3), 2021 | 7 | 2021 |
| Atezolizumab as the first systemic therapy approved for alveolar soft part sarcoma EJ Bergsma, M Elgawly, D Mancuso, R Orr, T Vuskovich, ND Seligson Annals of Pharmacotherapy 58 (4), 407-415, 2024 | 6 | 2024 |
John HaysAssociate Professor, The Ohio State University James Cancer Hospital在 osumc.edu 的电子邮件经过验证
